Disclosures The data in this paper were presented in part at the 16th European Meeting on Hypertension, Madrid, Spain, 12–15 June 2006. Noemi Muszbek and Agnes Benedict are employees of United BioSource. As a research organisation, United BioSource conducted the original literature review upon which this article is based. United BioSource has undertaken similar projects for other pharmaceutical companies. Abdulkadir Keskinaslan and Zeba M Khan are directly employed by Novartis Pharma AG and Novartis Pharmaceuticals Corporation respectively. Diana Brixner has received unrestricted research grants from Novartis Pharma AG. However, she has not received an honorarium to author this manuscript. Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
Version of Record online: 11 JAN 2008
International Journal of Clinical Practice
Volume 62, Issue 2, pages 338–351, February 2008
How to Cite
Muszbek, N., Brixner, D., Benedict, A., Keskinaslan, A. and Khan, Z. M. (2008), The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. International Journal of Clinical Practice, 62: 338–351. doi: 10.1111/j.1742-1241.2007.01683.x
- Issue online: 11 JAN 2008
- Version of Record online: 11 JAN 2008
- Paper received July 2007, accepted December 2007
- 5World Health Organization (WHO). The World Health Report 2002: Reducing Risks, Promoting Healthy Life. WHO, http://www.who.int/whr/2002/en/whr02_en.pdf (accessed July 2007).
- 6Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.
- 18World Health Organization (WHO). Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO, 2003.
- 19Medication Compliance and Persistence Special Interest Group (MCP). Accomplishments. International Society for Pharmacoeconomics & Outcomes Research (ISPOR), http://www.ispor.org/sigs/MCP_accomplishments.asp#definition (accessed July 2007).
- 44GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
- 50Patient compliance and persistence with combination valsartan/hydrochlorothiazide therapy versus hydrochlorothiazide therapy. New York: Poster presented at American Society of Hypertension (ASH) meeting, 2004., , et al.
- 51A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): S2–6..
- 52Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. J Hypertens 2005; 23 (Suppl. 2): S236., , et al.